- Home
- SLXNW
as 11-15-2024 4:00pm EST
Stocks
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
| Founded: | N/A | Country: | Israel |
| Employees: | N/A | City: | MODIIN-MACCABIM-REUT |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Biomotion Sciences Warrant News
SLXNW Breaking Stock News: Dive into SLXNW Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 days ago
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
ACCESSWIRE
a month ago
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
Business Wire
2 months ago
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
Business Wire
2 months ago
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
Business Wire
2 months ago
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
GlobeNewswire
2 months ago
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
Compare SLXNW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLXNW Biomotion Sciences Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.